Iron supplements and the immune system in HHT
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Immune system & allergy clinical trials.
This study looks at how iron supplements affect the immune system in people with HHT (a genetic condition that causes bleeding from abnormal blood vessels). You may be placed in one of three groups depending on your iron and ferritin levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 or older) diagnosed with HHT (a condition that causes abnormal blood vessels).
- You must have a confirmed genetic mutation in one of the genes linked to HHT (ENG, ACVRL1, or MADH4).
- You need to be part of the CIROCO study (a long-term research registry for HHT).
- Your iron level (ferritin) will determine which group you can join – some groups require iron levels above 25, while one group requires levels below 25.
- You cannot have received iron supplements (pills or IV) or a blood transfusion in the last 3 months, unless you are in the group that allows ongoing iron therapy.
- You should not have active cancer, a recent infection, or an autoimmune disease that alters your immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving iron supplements to patients who have anemia and inflammation during a hospital stay can help improve their iron levels and overall health. It aims to see if this treatment is safe and effective for people in this situation.
This trial tests whether nintedanib can reduce how often and how severe nosebleeds are in adults with hereditary hemorrhagic telangiectasia (HHT). It may help by calming blood-vessel problems that cause bleeding.
This trial tests an investigational drug, TX002100, for people with hereditary hemorrhagic telangiectasia (HHT) who need regular intravenous iron infusions or blood transfusions to manage bleeding. The goal is to see if it reduces the need for these supportive treatments.
This study evaluates the heart health of people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes abnormal blood vessels. By participating, you help doctors understand how HHT affects the heart, which may improve future care.
This study looks at how “low-oxygen” signals may affect people with hereditary hemorrhagic telangiectasia (HHT), a genetic bleeding disorder. It may help researchers understand what drives symptoms and could guide future treatments.
This trial tests an experimental pill, engasertib, to reduce frequent nosebleeds in adults with a rare blood vessel condition called hereditary hemorrhagic telangiectasia (HHT). Participation may help if you have moderate to severe nosebleeds and need iron or blood transfusions.
Hear when a new Hereditary Haemorrhagic Telangiectasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.